Literature DB >> 28445830

Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.

Ping Liu1, Dan Ma1, Zhengyu Yu1, Nana Zhe1, Mei Ren1, Ping Wang1, Meisheng Yu2, Jun Huang1, Qin Fang3, Jishi Wang4.   

Abstract

Neoplasm cells from patients with chronic myeloid leukemia (CML) interact with stromal cells of the surrounding microenvironment. Bone marrow stromal cells (BMSCs) represent the main population in CML marrow stroma, which may play a key role in disease support and progression. Heme oxygenase-1 (HO-1) is a key enzyme of antioxidative metabolism that is associated with cell proliferation and resistance to apoptosis. We herein up-regulated HO-1 expression of BMSCs and evaluated whether BMSCs influenced K562 cells survival. BMSCs were isolated from the bone marrow of normal people and CML patients. Following co-culture of BMSCs and K562 cells, up-regulating HO-1 expression in bone marrow stromal cells increased the imatinib (IM) resistance of K562 cells, whereas the apoptosis of K562 cells was effectively promoted without BMSCs co-culture. The protection may be mediated by CXCL12 (stromal derived factors 1, SDF-1)/CXCR4 signaling. The CXCL12/CXCR4 interaction significantly enhanced the phosphorylation of AKT. As far as drug resistance was concerned, BMSCs counteracted the cytotoxic effect of IM administration in vitro, and they protected K562 cells from the apoptosis induced by kinase inhibitor IM. The regulated HO-1 expression of BMSCs provides a new putative target for CML therapy.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chronic myeloid leukemia; Heme oxygenase-1; Imatinib; Microenvironment; Resistance

Mesh:

Substances:

Year:  2017        PMID: 28445830     DOI: 10.1016/j.biopha.2017.04.076

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.

Authors:  Xinyao Li; Zhengchang He; Bingqing Cheng; Qin Fang; Dan Ma; Tingting Lu; Danna Wei; Xingyi Kuang; Sishi Tang; Jie Xiong; Jishi Wang
Journal:  Cancer Biol Ther       Date:  2018-07-03       Impact factor: 4.742

2.  Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4.

Authors:  Tianzhen Hu; Chengyun Pan; Tianzhuo Zhang; Ming Ni; Weili Wang; Siyu Zhang; Ying Chen; Jishi Wang; Qin Fang
Journal:  Cancer Gene Ther       Date:  2022-07-15       Impact factor: 5.854

3.  3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma.

Authors:  Min Feng; Jia Wang; Ming Sun; Guilan Li; BingXiang Li; Han Zhang
Journal:  Cancer Cell Int       Date:  2021-05-26       Impact factor: 5.722

4.  Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway.

Authors:  Zhen Zhou; Dan Ma; Peifan Li; Ping Wang; Ping Liu; Danna Wei; Jun Wang; Zhong Qin; Qin Fang; Jishi Wang
Journal:  Aging (Albany NY)       Date:  2020-06-22       Impact factor: 5.682

5.  Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway.

Authors:  Yanfang Song; Qing Lin; Zhaolian Cai; Taisen Hao; Yaohan Zhang; Xianjin Zhu
Journal:  Cancer Sci       Date:  2019-06-18       Impact factor: 6.716

6.  Circular RNA regulatory network reveals cell-cell crosstalk in acute myeloid leukemia extramedullary infiltration.

Authors:  Chengfang Lv; Lili Sun; Zhibo Guo; Huibo Li; Desheng Kong; Bingqi Xu; Leilei Lin; Tianjiao Liu; Dan Guo; Jin Zhou; Yinghua Li
Journal:  J Transl Med       Date:  2018-12-17       Impact factor: 5.531

Review 7.  Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment.

Authors:  Yidi Qu; Bo Dou; Horyue Tan; Yibin Feng; Ning Wang; Di Wang
Journal:  Mol Cancer       Date:  2019-03-30       Impact factor: 27.401

8.  CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia.

Authors:  Tianzhuo Zhang; Danna Wei; Tingting Lu; Dan Ma; Kunlin Yu; Qin Fang; Zhaoyuan Zhang; Weili Wang; Jishi Wang
Journal:  RSC Adv       Date:  2020-01-03       Impact factor: 4.036

9.  Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.

Authors:  Zhaoyuan Zhang; Weili Wang; Dan Ma; Jie Xiong; Xingyi Kuang; Siyu Zhang; Qin Fang; Jishi Wang
Journal:  Aging (Albany NY)       Date:  2020-04-16       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.